Last reviewed · How we verify
PF-06439535 (CN) (pf-06439535-cn)
Selective inhibitor blocking proteins that drive abnormal cell growth and division in cancer cells.
PF-06439535 (CN) is a Pfizer-developed selective inhibitor designed to target key cellular pathways driving abnormal cell growth, positioned as a potential competitor to bevacizumab in advanced non-squamous non-small-cell lung cancer (NSCLC). The drug was evaluated in a Phase 3 bridging study comparing PF-06439535 (CN) plus paclitaxel-carboplatin versus the standard-of-care bevacizumab plus paclitaxel-carboplatin regimen; however, the program was terminated after enrollment of only 8 patients, indicating insufficient clinical efficacy or strategic deprioritization. Despite regulatory authorizations noted in EMA and MHRA databases, the drug has been discontinued and never achieved commercial launch, suggesting the clinical data did not support advancement or the company reallocated resources to higher-priority oncology assets. The program's failure to progress beyond early Phase 3 reflects the competitive intensity in NSCLC therapy and the high bar for demonstrating superiority over established anti-angiogenic agents. No published clinical data, revenue figures, or ongoing development activities are available in the public domain.
At a glance
| Generic name | pf-06439535-cn |
|---|---|
| Sponsor | Pfizer Inc. |
| Drug class | Selective pathway inhibitor; presumed anti-angiogenic agent |
| Target | Not publicly disclosed; presumed to be VEGF pathway or related angiogenic target based on clinical trial design |
| Therapeutic area | Oncology |
| Phase | discontinued |
Mechanism of action
PF-06439535 (CN) functions as a selective inhibitor targeting key cellular pathways implicated in oncogenic transformation and tumor progression. By blocking specific proteins responsible for driving abnormal cell proliferation and division, the drug aims to halt cancer cell growth and induce apoptosis. The mechanism was designed to provide anti-angiogenic or anti-proliferative activity comparable to or superior to bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor (VEGF), in the treatment of advanced NSCLC. The selective nature of the inhibitor suggests a narrower target profile intended to maximize efficacy while potentially reducing off-target toxicity.
Approved indications
Pipeline indications
- Advanced non-squamous non-small-cell lung cancer (NSCLC) — Phase 3
Common side effects
Key clinical trials
- A BRIDGING STUDY OF PF-06439535 (CN) PLUS PACLITAXEL-CARBOPLATIN VERSUS BEVACIZUMAB PLUS PACLITAXEL-CARBOPLATIN IN NSCLC (PHASE3)
- A SINGLE-DOSE, 2-ARM, PHARMACOKINETIC STUDY OF PF-06439535 (CN) AND EUROPEAN UNION SOURCED BEVACIZUMAB IN CHINESE HEALTHY MALE VOLUNTEERS (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PF-06439535 (CN) CI brief — competitive landscape report
- PF-06439535 (CN) updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI